|1.||Molkentin, Jeffery D: 2 articles (12/2011 - 08/2006)|
|2.||Jouan, Elodie: 1 article (01/2015)|
|3.||Bruyere, Arnaud: 1 article (01/2015)|
|4.||Mayati, Abdullah: 1 article (01/2015)|
|5.||Fardel, Olivier: 1 article (01/2015)|
|6.||Parmentier, Yannick: 1 article (01/2015)|
|7.||Denizot, Claire: 1 article (01/2015)|
|8.||Moreau, Amélie: 1 article (01/2015)|
|9.||Tatsugami, Katsunori: 1 article (02/2014)|
|10.||Shiota, Masaki: 1 article (02/2014)|
|1.||Prostatic Neoplasms (Prostate Cancer)
02/15/2014 - "Ro31-8220 suppressed cell proliferation in androgen-dependent prostate cancer LNCaP cells, which was augmented by its combination with androgen deprivation or enzalutamide. "
02/15/2014 - "In this study, we aimed to elucidate the role of PKC/Twist1 signaling in castration resistance, and to apply this information to the development of a novel therapeutic concept using PKC inhibitor Ro31-8220 against prostate cancer using various prostate cancer cell lines. "
|2.||Brain Neoplasms (Brain Tumor)
09/01/1998 - "Ro 31-8220, in particular, might be a useful agent for the treatment of human brain tumors."
09/01/1998 - "This study demonstrates that the staurosporine derivative Ro 31-8220, a potent PKC inhibitor, inhibited the growth of 7 human brain tumor cell lines with an IC50 of about 2 microM. "
05/01/2000 - "Inhibition of PKC by RO 31-8220 reduces the phagocytosis of latex particles and the release of superoxide, prostaglandin E(2) (PGE(2)), and tumour necrosis factor (TNF)-alpha. "
12/01/2011 - "TEMPO (a well known free radical scavenger) and Ro 31-8220 (an inhibitor of classical PKCs) prevented the inhibition of spontaneous and intrinsic apoptosis pathway (characterised by Bcl-xL induction, Bax down-regulation, caspases inhibition) and the induction of necrosis by lindane in rat hepatocytes. "
03/01/2004 - "Wortmannin (a PI3K inhibitor) reduced the stimulatory action of insulin on glycogen synthase a activity and blocked that of GLP-1, rapamycin (a 70s6k inhibitor) did not affect the action of GLP-1 but abolished that of insulin, PD98059 (MAPK inhibitor) was ineffective on insulin but blocked the action of GLP-1, okadaic acid (a PP-2A inhibitor) and tumour necrosis factor-alpha (a PP-1 inhibitor) were both ineffective on GLP-1 but abolished the action of insulin, and Ro 31-8220 (an inhibitor of some PKC isoforms) reduced the effect of GLP-1 while completely preventing that of insulin. "
06/01/2011 - "Inhibition of PKC by Ro-31-8220 and a dominant-negative construct of PKC-ε attenuated hypoxia-induced contraction of isolated pulmonary endothelial cells. "
10/01/2001 - "PMA, an agonist of PKC could reduce the expression of cNOS mNRA in hypoxia, while RO 31-8220, an inhibitor of PKC could inhibit it and enhance the expression of NOS mRNA(P < 0.01). "
04/18/2001 - "The protein kinase C inhibitors GF 109 203X and RO-31-8220 did not prevent the enhancement of muscarine-evoked release caused by chronic hypoxia. "
|5.||Melanoma (Melanoma, Malignant)
06/01/2004 - "Treatment of human melanoma cells with the selective PKC inhibitor Ro-31-8220 resulted in a significant increase of cell proliferation as measured by (3)H-thymidine incorporation and a fluorometric microassay. "
09/01/1994 - "The melanogenic responses to 1-oleoyl-2-acetylglycerol and ultraviolet radiation were unaffected by inhibition of protein kinase C with Ro31-8220, or ablation by downregulation with 500 nM TPA, in human melanocytes and melanoma cells. "
|2.||Protein Kinase C
|6.||Interleukin-1alpha (Interleukin 1 alpha)
|7.||Glucagon-Like Peptide 1 (GLP 1)
|8.||Cyclooxygenase 2 (Cyclooxygenase-2)
|9.||70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)
|10.||Mitogen-Activated Protein Kinase Kinases (MEKs)